Dr. Lee of Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women's Hospital received consulting fees from Eli Lilly.)
Dr. Dietrich of Harvard Medical School and Massachusetts General Hospital received consulting fees from Unum Therapeutics and Blue Earth Diagnostics.)
Dr. Wen of Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital received research support from Agios, Astra Zeneca, Beigene, Eli Lily, Genentech/Roche, Kazia, Merck, MediciNova, Novartis, Oncoceutics, Sanofi-Aventis, Vascular Biogenics, and VBI Vaccines; is on the advisory board for Abbvie, Agios, Astra Zeneca, Agios, Eli Lilly, Genentech/Roche, Immunomic Therapeutics, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines; has received honorariums for speaking engagements Merck and Prime Oncology.)
Dr. Lukas of Northwestern University Feinberg School of Medicine received honorariums from AbbVie and Novocure for speaking engagements, from Eisai for consulting work, and from Monetris as an advisory board member.)
This article includes discussion of chemotherapy: neurologic complications and neurologic complications of systemic anticancer therapies. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.
Patients with cancer are living longer due to earlier diagnoses and remarkable improvements in treatments. Unfortunately, neurologic complications from chemotherapy remain a significant cause of morbidity and may play a role in limiting potential treatments. In addition, novel therapies such as small molecule tyrosine kinase inhibitors, immunotherapy, CAR T cell therapy, and various monoclonal antibodies have been associated with neurologic complications. Because treatments for therapy-induced neurotoxicity are limited, awareness of common neurologic complications is important to prevent permanent damage. The authors review common neurologic complications of both conventional chemotherapy and novel anti-cancer therapies in this article.
• Neurologic complications from systemic anticancer therapies impact quality of life and remain an important source of dose-limiting toxicity.
• The neurotoxicities of chemotherapy are widely known, but targeted agents and immunotherapies are also associated with neurologic complications.
• Early recognition and prevention may help avoid permanent neurologic damage.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.